| abstract |
The present invention relates to modified proteins and peptides that have a reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules may contain C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (eg, fusions and conjugates) include proteins, peptides, antigen-binding molecules, antibodies or antibody fragments such as single variable domains, such as human immunoglobulin (antibody) single variable domains, and Single variable domains, such as VHHs, derived from non-human sources such as llamas or camels, including nanobody™ (eg as described in WO 94/04678 and WO 95/04079, among others). The present invention further relates to uses, formulations, compositions of molecules comprising such modified C-terminal extensions and/or amino acid substitutions, and also to methods of production and expression of these molecules. |